Nancy L Diaz

Columbia University, New York City, New York, United States

Are you Nancy L Diaz?

Claim your profile

Publications (3)10.79 Total impact

  • Nancy L Diaz, Era K Hanspal, Pietro Mazzoni
    Movement Disorders 09/2011; 27(2):328-9. · 4.56 Impact Factor
  • Source
    Nancy L Diaz, Elan D Louis
    [show abstract] [hide abstract]
    ABSTRACT: Although small treatment trials have examined the efficacy of front-line medications in tremor reduction in essential tremor (ET), an overall survey of pharmacological management has not been undertaken in a large sample of ET cases. To conduct a survey of medication usage among several hundred ET patients. A computerized database at the Neurological Institute of New York was used to identify 223 ET patients cared for by movement disorder neurologists and 37 cared for by general neurologists. Each had been seen one or more times within past five years. Lifetime treatment data were abstracted from clinical records. One-hundred-sixty-three (73.1%) of 223 patients cared for by movement disorder neurologists had taken medication for ET during their lifetime; 53/163 (32.5%) had taken ≥4 medications; 31/163 (19.0%) had taken ≥5 medications; and 3 (1.8%), ≥10 medications. Nearly three-quarters (158/223 [70.9%]) had taken primidone or propranolol, yet 89/158 (56.3%) had discontinued both. Among 11 patients who had undergone ET surgery, the mean number of ET medications tried was 6.0 ± 2.8 (range = 3-12). Medication usage by general neurologists was less than by movement disorder specialists (p < 0.001). One-third of general neurologists' patients (14/37 [37.8%]) had taken primidone or propranolol at some point and 6/14 (42.9%) had discontinued both. In this large survey, a substantial proportion of ET patients failed treatment with both front-line medications. Among patients seeing movement disorder specialists, the number of medications they had had to try was sizable. These data demonstrate the limitations of current pharmacological options for ET.
    Parkinsonism & Related Disorders 11/2010; 16(9):604-7. · 3.27 Impact Factor
  • Nancy L Diaz, Cheryl H Waters
    [show abstract] [hide abstract]
    ABSTRACT: Parkinson's disease is a progressive, neurodegenerative disorder affecting millions of people worldwide. Given the aging population, the prevalence of the disease is expected to increase substantially. The mainstay of treatment has been dopamine replacement therapy with carbidopa, levodopa, dopamine agonists, monoamine oxidase type B inhibitors, catechol-O-methyltransferase inhibitors and amantadine. Nonmotor features, such as cognitive impairment, mood disorders, autonomic dysfunction, gastrointestinal and genitourinary dysfunction, have a substantial impact on Parkinson's disease patients and their quality of life. This review will provide an overview on medications currently available for management of both motor and nonmotor symptoms of Parkinson's disease. Focus will be placed on recent and evolving studies evaluating symptomatic and neuroprotective effects of medications, and how such studies may impact the future management of Parkinson's disease.
    Expert Review of Neurotherapeutics 12/2009; 9(12):1781-9. · 2.96 Impact Factor